Originally published as JCO Early Release 10.1200/JCO.2005.07.799 on March 14 2005
Journal of Clinical Oncology, Vol 23, No 11 (April 10), 2005: pp. 2556-2568
© 2005 American Society of Clinical Oncology.
Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions
William Pao,
Vincent A. Miller
From the Program in Cancer Biology and Genetics and the Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; and Weill Medical College of Cornell University, New York, NY
Address reprint requests to William Pao, MD, PhD, Varmus Lab—Box 62, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; email: paow{at}mskcc.org.
PURPOSE: Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the clinic, the specific targets affected in human tumors were unknown. In April 2004, two groups reported that mutations in the tyrosine kinase domain of EGFR are strongly associated with gefitinib sensitivity in patients with non–small-cell lung cancer (NSCLC). We subsequently extended these findings and showed that such mutations are also associated with sensitivity to erlotinib. Here, we present current knowledge about EGFR mutations in the context of clinical trials involving gefitinib and erlotinib in NSCLC.
DESIGN: This article reviews the rationale for targeting EGFR, the development of gefitinib and erlotinib, the discovery of EGFR mutations, and subsequent studies to define the incidence, spectrum, and functions of EGFR mutations.
RESULTS: The discovery of EGFR mutations promises to alter the ways in which we consider and treat NSCLC.
CONCLUSION: This information can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC.
W.P. is supported by the CHEST and LUNGevity Foundation Clinical Research Award in Lung Cancer 2004.
Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. SHUKUYA, T. TAKAHASHI, A. TAMIYA, A. ONO, S. IGAWA, Y. NAKAMURA, A. TSUYA, H. MURAKAMI, T. NAITO, K. KAIRA, et al.
Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to Gefitinib
Anticancer Res,
July 1, 2009;
29(7):
2747 - 2751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. PESEK, L. BENESOVA, B. BELSANOVA, P. MUKENSNABL, F. BRUHA, and M. MINARIK
Dominance of EGFR and Insignificant KRAS Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status
Anticancer Res,
July 1, 2009;
29(7):
2767 - 2773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hogan, Jing Jie Yu, H J. Williams, R. Altaha, Xiaobing Liang, and Qi He
Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib
Journal of Oncology Pharmacy Practice,
June 1, 2009;
15(2):
111 - 117.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. S. Andrew, R. A. Mason, V. Memoli, and E. J. Duell
Arsenic Activates EGFR Pathway Signaling in the Lung
Toxicol. Sci.,
June 1, 2009;
109(2):
350 - 357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Stinchcombe and M. A. Socinski
Current Treatments for Advanced Stage Non-Small Cell Lung Cancer
Proceedings of the ATS,
April 15, 2009;
6(2):
233 - 241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, M. Bavieri, B. Murer, E. Meschiari, S. Tamberi, et al.
EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors
Am J Clin Pathol,
April 1, 2009;
131(4):
478 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Scagliotti, N. Hanna, F. Fossella, K. Sugarman, J. Blatter, P. Peterson, L. Simms, and F. A. Shepherd
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Oncologist,
March 1, 2009;
14(3):
253 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Nose, K. Sugio, T. Oyama, T. Nozoe, H. Uramoto, T. Iwata, T. Onitsuka, and K. Yasumoto
Association Between Estrogen Receptor-{beta} Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung
J. Clin. Oncol.,
January 20, 2009;
27(3):
411 - 417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Di Nicolantonio, S. Arena, M. Gallicchio, D. Zecchin, M. Martini, S. E. Flonta, G. M. Stella, S. Lamba, C. Cancelliere, M. Russo, et al.
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
PNAS,
December 30, 2008;
105(52):
20864 - 20869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Fichtner, J. Rolff, R. Soong, J. Hoffmann, S. Hammer, A. Sommer, M. Becker, and J. Merk
Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
Clin. Cancer Res.,
October 15, 2008;
14(20):
6456 - 6468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Girnun, L. Chen, J. Silvaggi, R. Drapkin, L. R. Chirieac, R. F. Padera, R. Upadhyay, S. B. Vafai, R. Weissleder, U. Mahmood, et al.
Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin
Clin. Cancer Res.,
October 15, 2008;
14(20):
6478 - 6486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Fischer, N. Taylor, S. Allerstorfer, M. Grusch, G. Sonvilla, K. Holzmann, U. Setinek, L. Elbling, H. Cantonati, B. Grasl-Kraupp, et al.
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Mol. Cancer Ther.,
October 1, 2008;
7(10):
3408 - 3419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Schilsky, G. Gordon, T. M. Gilmer, S. A. Courtneidge, L. M. Matrisian, O. Grad, W. G. Nelson, and on behalf of the Translational Research Working Gr
The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics)
Clin. Cancer Res.,
September 15, 2008;
14(18):
5685 - 5691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Stinchcombe and M. A. Socinski
Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
Oncologist,
September 1, 2008;
13(9):
933 - 944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Pitini, C. Arrigo, and G. Altavilla
Erlotinib in a Patient With Acute Myelogenous Leukemia and Concomitant Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
July 20, 2008;
26(21):
3645 - 3646.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, G. Sala, S. Cedres, S. Peralta, H. Maacke, D. Foernzler, et al.
A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
Clin. Cancer Res.,
June 15, 2008;
14(12):
3867 - 3874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kudoh, H. Kato, Y. Nishiwaki, M. Fukuoka, K. Nakata, Y. Ichinose, M. Tsuboi, S. Yokota, K. Nakagawa, M. Suga, et al.
Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study
Am. J. Respir. Crit. Care Med.,
June 15, 2008;
177(12):
1348 - 1357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kondo, T. Tanaka, T. Miyake, T. Ichikawa, M. Hirai, M. Adachi, K. Yoshikawa, K. Ichimura, N. Ohara, A. Moriwaki, et al.
Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines
Mol. Cancer Ther.,
June 1, 2008;
7(6):
1461 - 1471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. N. Vinageras, A. de la Torre, M. O. Rodriguez, M. C. Ferrer, I. Bravo, M. M. del Pino, D. A. Abreu, S. A. Brooks, R. Rives, C. del Castillo Carrillo, et al.
Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
March 20, 2008;
26(9):
1452 - 1458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peipp, T. Schneider-Merck, M. Dechant, T. Beyer, J. J. Lammerts van Bueren, W. K. Bleeker, P. W. H. I. Parren, J. G. J. van de Winkel, and T. Valerius
Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations
J. Immunol.,
March 15, 2008;
180(6):
4338 - 4345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, B. C. Mennecier, W. Pfeifer, K. J. O'Byrne, T. Welte, R. Kolb, et al.
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Ann. Onc.,
February 1, 2008;
19(2):
362 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bean, C. Brennan, J.-Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, et al.
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
PNAS,
December 26, 2007;
104(52):
20932 - 20937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. K. Tan, J. Wang, P.-L. H. Littler, K. K. Wong, T. A. Sweetnam, W. Keefe, N. R. Nash, E. C. Reding, F. Piu, M. R. Brann, et al.
Monitoring Interactions between Receptor Tyrosine Kinases and Their Downstream Effector Proteins in Living Cells Using Bioluminescence Resonance Energy Transfer
Mol. Pharmacol.,
December 1, 2007;
72(6):
1440 - 1446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Edwards, J. Li, P. Atadja, K. Bhalla, and E. B. Haura
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor dependent human lung cancer cells
Mol. Cancer Ther.,
September 1, 2007;
6(9):
2515 - 2524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Riely, M. G. Kris, B. Zhao, T. Akhurst, D. T. Milton, E. Moore, L. Tyson, W. Pao, N. A. Rizvi, L. H. Schwartz, et al.
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
Clin. Cancer Res.,
September 1, 2007;
13(17):
5150 - 5155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Karamouzis, J. R. Grandis, and A. Argiris
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
JAMA,
July 4, 2007;
298(1):
70 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Finberg, L. V. Sequist, V. A. Joshi, A. Muzikansky, J. M. Miller, M. Han, J. Beheshti, L. R. Chirieac, E. J. Mark, and A. J. Iafrate
Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features
J. Mol. Diagn.,
July 1, 2007;
9(3):
320 - 326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Horiike, H. Kimura, K. Nishio, F. Ohyanagi, Y. Satoh, S. Okumura, Y. Ishikawa, K. Nakagawa, T. Horai, and M. Nishio
Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer
Chest,
June 1, 2007;
131(6):
1628 - 1634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Braiteh and R. Kurzrock
Uncommon tumors and exceptional therapies: paradox or paradigm?
Mol. Cancer Ther.,
April 1, 2007;
6(4):
1175 - 1179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor
Clin. Cancer Res.,
March 1, 2007;
13(5):
1540 - 1551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Subramanian and R. Govindan
Lung Cancer in Never Smokers: A Review
J. Clin. Oncol.,
February 10, 2007;
25(5):
561 - 570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Rho, Y. J. Choi, B.-Y. Ryoo, I. I. Na, S. H. Yang, C. H. Kim, and J. C. Lee
p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non-Small Cell Lung Cancer
Cancer Res.,
February 1, 2007;
67(3):
1163 - 1169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Karamouzis, P. A. Konstantinopoulos, and A. G. Papavassiliou
The Activator Protein-1 Transcription Factor in Respiratory Epithelium Carcinogenesis
Mol. Cancer Res.,
February 1, 2007;
5(2):
109 - 120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Okano, T. Kondo, K. Fujii, T. Nishimura, T. Takano, Y. Ohe, K. Tsuta, Y. Matsuno, A. Gemma, H. Kato, et al.
Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Clin. Cancer Res.,
February 1, 2007;
13(3):
799 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Schiffer, E. C. Reding, S. R. Fuhs, Q. Lu, F. Piu, S. Wong, P.-L. H. Littler, D. M. Weiner, W. Keefe, P. K. Tan, et al.
Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer
Mol. Pharmacol.,
February 1, 2007;
71(2):
508 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Chin, D. Anuar, R. Soo, M. Salto-Tellez, W. Q. Li, B. Ahmad, S. C. Lee, B. C. Goh, K. Kawakami, A. Segal, et al.
Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC
Clin. Chem.,
January 1, 2007;
53(1):
62 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Riely, K. A. Politi, V. A. Miller, and W. Pao
Update on Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Clin. Cancer Res.,
December 15, 2006;
12(24):
7232 - 7241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke
Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL
Mol. Cancer Ther.,
December 1, 2006;
5(12):
3170 - 3180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Levis, P. Brown, B. D. Smith, A. Stine, R. Pham, R. Stone, D. DeAngelo, I. Galinsky, F. Giles, E. Estey, et al.
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Blood,
November 15, 2006;
108(10):
3477 - 3483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Balak, Y. Gong, G. J. Riely, R. Somwar, A. R. Li, M. F. Zakowski, A. Chiang, G. Yang, O. Ouerfelli, M. G. Kris, et al.
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors.
Clin. Cancer Res.,
November 1, 2006;
12(21):
6494 - 6501.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Su, C. Bodenstein, R. A. Dumont, Y. Seimbille, S. Dubinett, M. E. Phelps, H. Herschman, J. Czernin, and W. Weber
Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5659 - 5667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, and T. Mitsudomi
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5764 - 5769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W. Yip, X. Mao, P.Y. B. Au, D. W. Hedley, S. Chow, S. Dalili, J. D. Mocanu, C. Bastianutto, A. Schimmer, and F.-F. Liu
Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen.
Clin. Cancer Res.,
September 15, 2006;
12(18):
5557 - 5569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Carey, A. J. Garton, M. S. Romero, J. Kahler, S. Thomson, S. Ross, F. Park, J. D. Haley, N. Gibson, and M. X. Sliwkowski
Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
Cancer Res.,
August 15, 2006;
66(16):
8163 - 8171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Park, H. J. Jun, M. J. Cho, K. H. Cho, J. S. Lee, J. I. Zo, and H. Pyo
Radiosensitivity Enhancement by Combined Treatment of Celecoxib and Gefitinib on Human Lung Cancer Cells.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4989 - 4999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. N. Blehm, P. E. Spiess, J. E. Bondaruk, M. E. Dujka, G. J. Villares, Y.-j. Zhao, O. Bogler, K. D. Aldape, H. B. Grossman, L. Adam, et al.
Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy
Clin. Cancer Res.,
August 1, 2006;
12(15):
4671 - 4677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Zakowski, M. Ladanyi, M. G. Kris, and the Memorial Sloan-Kettering Cancer Center Lung Ca
EGFR mutations in small-cell lung cancers in patients who have never smoked.
N. Engl. J. Med.,
July 13, 2006;
355(2):
213 - 215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Mol. Cancer Ther.,
June 1, 2006;
5(6):
1387 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-K. Toh, F. Gao, W.-T. Lim, S.-S. Leong, K.-W. Fong, S.-P. Yap, A. A.L. Hsu, P. Eng, H.-N. Koong, A. Thirugnanam, et al.
Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity
J. Clin. Oncol.,
May 20, 2006;
24(15):
2245 - 2251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, et al.
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
PNAS,
May 16, 2006;
103(20):
7817 - 7822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goodin
Erlotinib: optimizing therapy with predictors of response?
Clin. Cancer Res.,
May 15, 2006;
12(10):
2961 - 2963.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Calvo and J. Baselga
Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
J. Clin. Oncol.,
May 10, 2006;
24(14):
2158 - 2163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Janmaat, M. I. Gallegos-Ruiz, J. A. Rodriguez, G. A. Meijer, W. L. Vervenne, D. J. Richel, C. Van Groeningen, and G. Giaccone
Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients
J. Clin. Oncol.,
April 1, 2006;
24(10):
1612 - 1619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Alvarez, H. Greulich, W. R. Sellers, M. Meyerson, and D. A. Frank
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
Cancer Res.,
March 15, 2006;
66(6):
3162 - 3168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Riely, W. Pao, D. Pham, A. R. Li, N. Rizvi, E. S. Venkatraman, M. F. Zakowski, M. G. Kris, M. Ladanyi, and V. A. Miller
Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Clin. Cancer Res.,
February 1, 2006;
12(3):
839 - 844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhou, S. Li, Y. P. Hu, J. Wang, J. Hauser, A. N. Conway, M. A. Vinci, L. Humphrey, E. Zborowska, J. K.V. Willson, et al.
Blockade of EGFR and ErbB2 by the Novel Dual EGFR and ErbB2 Tyrosine Kinase Inhibitor GW572016 Sensitizes Human Colon Carcinoma GEO Cells to Apoptosis
Cancer Res.,
January 1, 2006;
66(1):
404 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C S L Lai, C Boshoff, M Falzon, and S M Lee
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC
Thorax,
January 1, 2006;
61(1):
91 - 91.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Wild, K. Fager, C. Flefleh, D. Kan, I. Inigo, S. Castaneda, F. Luo, A. Camuso, K. McGlinchey, and W. C. Rose
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels
Mol. Cancer Ther.,
January 1, 2006;
5(1):
104 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu, L. Fu, T. Q. Pham, R. Soriano, J. Stinson, S. Seshagiri, et al.
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
Clin. Cancer Res.,
December 15, 2005;
11(24):
8686 - 8698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Arora and E. M. Scholar
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
J. Pharmacol. Exp. Ther.,
December 1, 2005;
315(3):
971 - 979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Haura, Z. Zheng, L. Song, A. Cantor, and G. Bepler
Activated Epidermal Growth Factor Receptor-Stat-3 Signaling Promotes Tumor Survival In vivo in Non-Small Cell Lung Cancer
Clin. Cancer Res.,
December 1, 2005;
11(23):
8288 - 8294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E.W. Cohen, M. A. Kane, M. A. List, B. E. Brockstein, B. Mehrotra, D. Huo, A. M. Mauer, C. Pierce, A. Dekker, and E. E. Vokes
Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res.,
December 1, 2005;
11(23):
8418 - 8424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Moroni, A. Sartore-Bianchi, S. Benvenuti, S. Artale, A. Bardelli, and S. Siena
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer
Ann. Onc.,
November 1, 2005;
16(11):
1848 - 1849.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nabhan, J. D. Bitran, T. Takano, Y. Ohe, W. Pao, M. Ladanyi, V. A. Miller, the Lung Cancer Oncogenome Group, F. A. Shepherd, L. Seymour, et al.
Erlotinib in lung cancer.
N. Engl. J. Med.,
October 20, 2005;
353(16):
1739 - 1741.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Walgren, M. A. Meucci, and H. L. McLeod
Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?
J. Clin. Oncol.,
October 10, 2005;
23(29):
7342 - 7349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. G. Kris
How Today's Developments in the Treatment of Non-Small Cell Lung Cancer Will Change Tomorrow's Standards of Care
Oncologist,
October 1, 2005;
10(suppl_2):
23 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Movsas
Will Future Progress in Non-Small-Cell Lung Cancer Be Step by Step ... or by Leaps and Bounds?
J. Clin. Oncol.,
September 1, 2005;
23(25):
5859 - 5861.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens
Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R))
Oncologist,
September 1, 2005;
10(8):
579 - 589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Wasil and S. M. Lichtman
Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Oncologist,
September 1, 2005;
10(8):
602 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Pan, W. Pao, and M. Ladanyi
Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas
J. Mol. Diagn.,
August 1, 2005;
7(3):
396 - 403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Doroshow
Targeting EGFR in Non-Small-Cell Lung Cancer
N. Engl. J. Med.,
July 14, 2005;
353(2):
200 - 202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Tonon, K.-K. Wong, G. Maulik, C. Brennan, B. Feng, Y. Zhang, D. B. Khatry, A. Protopopov, M. J. You, A. J. Aguirre, et al.
High-resolution genomic profiles of human lung cancer
PNAS,
July 5, 2005;
102(27):
9625 - 9630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol.,
April 10, 2005;
23(11):
2445 - 2459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. VARMUS, W. PAO, K. POLITI, K. PODSYPANINA, and Y.-C.N. DU
Oncogenes Come of Age
Cold Spring Harb Symp Quant Biol,
January 1, 2005;
70(0):
1 - 9.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L.C. AMLER, A.D. GODDARD, and K.J. HILLAN
Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Cold Spring Harb Symp Quant Biol,
January 1, 2005;
70(0):
483 - 488.
[Abstract]
[PDF]
|
|
|
|
